Ferraro, DA

Meyers, JP

Saltz, L

Seymour, MT

Shi, Q

Zalcberg, JR

White Rose Research Online

Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database

13/07/2018 Meeting Library | Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) pati…https://meetinglibrary.asco.org/record/155538/abstract 1/2Associations of incidence of common adverse events (AEs) and survivaloutcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with  rstline chemotherapy: Findings from 9,812 pts in the ARCAD database.Presented Saturday, January 20, 2018Authors:Danielle Angela Ferraro, John Raymond Zalcberg, Qian Shi, Je rey P. Meyers, Matthew T. Seymour,Leonard Saltz, Tim Maughan, Richard M. Goldberg, Eric Van Cutsem, Volker Heinemann, HerbertHurwitz, Alfredo Falcone, Eduardo Diaz-Rubio, Benoist Chibaudel, Charles S. Fuchs, Rainer Porschen,Carsten Bokemeyer, Aimery De Gramont, Tim Price, Richard Adams; University of Melbourne,Melbourne, Australia; School of Public Health, Melbourne, Australia; Mayo Clinic, Rochester, MN;National Institute for Health Research Clinical Research Network, Leeds, United Kingdom; MemorialSloan Kettering Cancer Center, New York, NY; CRUK/MRC Oxford Institute for Radiation Oncology,Oxford, United Kingdom; West Virginia University Cancer Institute, Morgantown, WV; UniversityHospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium; Ludwig Maximilian University ofMunich, Munich, Germany; Duke University, Durham, NC; Azienda Ospedaliera-Universitaria Pisana,Pisa, Italy; CIBERONC, Madrid, Spain; Franco-British Institute, Levallois-Perret, France; Smilow CancerHospital, Yale New Haven Health, New Haven, CT; Klinikum Bremen-Ost, Bremen, Germany; UniversityMedical Center Hamburg-Eppendorf, Hamburg, Germany; Queen Elizabeth Hospital/ University ofAdelaide, Adelaide, Australia; Cardi  University, Cardi , United KingdomView LessAbstract DisclosuresBackground:There is limited, often con icting evidence about AE timing, severity or associations with outcomes withthe use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS)and progression-free survival (PFS) of selected common AEs (neutropenia, diarrhea, nausea, vomiting,neuropathy) occurring in patients receiving  rst line oxaliplatin (Oxa)- and/or irinotecan(Iri)-basedregimens for mCRC.Print13/07/2018 Meeting Library | Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) pati…https://meetinglibrary.asco.org/record/155538/abstract 2/2This content is made available for your personal use, educational advancement, or professional development. Unauthorized reproduction is prohibited. For permission tore-use for commercial or other purposes, please contact permissions@asco.orgMethods:The CTCAE grading scores of at least one AE of interest were available on 9812 pts treated withchemotherapy alone (median age 63; 62.4% male, 50.1% ECOG PS 0) from 17 1 -line randomizedtrials. Patients who also received biologics were excluded in the primary analyses. AEs occurring duringthe  rst 6 weeks of treatment and entire treatment were analyzed by strati ed multivariable Coxmodels in relationship to OS/PFS. 55.7% pts received Oxa- regimens, 35.7% Iri-regimens, and 8.6%combined Oxa- and Iri-regimens.Results:Within the  rst 6 weeks of treatment, G3+ neutropenia (HR = 1.3, 95% CI, 1.06-1.59, p  0.01),diarrhea (HR = 1.48, 95% CI, 1.23-1.79, p < .0001), nausea (HR = 1.53, 95% CI, 1.17-1.99, p0.002) and vomiting (HR = 1.56, 95% CI, 1.18-2.07, p  0.002) were associated with signi cantly worseOS for Iri-regimens, but only G3+ nausea predicted for worse OS for Oxa- regimens (HR = 1.61, 95%CI, 1.18-2.21, p  0.003). For AEs experienced at any time, G3+ neutropenia and neuropathy weresigni cantly associated with longer PFS and OS for Oxa-regimens, while G3+ vomiting and nausea wereassociated with worse OS for both Oxa- and Iri-based regimens. Sensitivity analysis showed largelyconcordant results by including pts who also received biologics.Conclusions:The association between more severe selected AEs and outcome varies between AEs and is in uencedby timing of the occurrence. More severe selected AEs occurring early in treatment are associated withworse outcomes. In contrast, for AEs occurring at any time, G3+ neutropenia and neuropathypredicted for longer PFS and/or OS in Oxa-treated pts.stadj adjadj adj adj adjadj adjadjadjPrint

https://eprints.whiterose.ac.uk/133334/1/Meeting%20Library%20_%20Associations%20of%20incidence%20of%20common%20adverse%20events%20%28AEs%29%20and%20survival%20outcomes%20in%20metastatic%20colorectal%20cancer%20%28mCRC%29%20patients%20%28pts%29%20treated%20with%20first%20line%20chemotherapy_%20Findings%20from%209%2C812%20pts%20in%20the%20ARCAD%20database_.pdf

Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database

Abstract

Similar works

Full text

Available Versions

White Rose Research Online

White Rose Research Online